![](https://www.eahealth.org/sites/www.eahealth.org/files/styles/800-16x9/public/content/research_programme/images/2018-04-24/KAKA1.jpg?itok=-87dNI7s&c=fd9a2e8cafb0dcff8ce01cda501c807e)
A phase 2 Open‐Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide during 8 weeks of treatment in Adult Subjects with Newly Diagnosed Drug‐Sensitive or Multi Drug‐ Resistant, Smear‐Positive Pulmonary Tuberculosis.